Carr Patricia's Form 4 filing
Jazz Pharmaceuticals plcJAZZ · filed Dec 9, 2025
- Accession no.
- 0001784606-25-000007
- Filed
- Dec 9, 2025
- Trade date
- Dec 5, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $797.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Carr PatriciaCIK 0001784606 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | Ordinary Shares | SSaleDisposed | −160 | $171.11 | −$27,377.6 | 7,012 | Direct | |
| Dec 5, 2025 | Ordinary Shares | MOption exerciseAcquired | +4,500 | $140.67 | +$633,015 | 11,512 | Direct | |
| Dec 5, 2025 | Ordinary Shares | SSaleDisposed | −4,500 | $171.20F2 | −$770,400 | 7,012 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | Ordinary Shares | MOption exerciseDisposed | −4,500 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $171.2001 to $171.2601. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.